<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="95927">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02047656</url>
  </required_header>
  <id_info>
    <org_study_id>CLFF269X2105</org_study_id>
    <nct_id>NCT02047656</nct_id>
  </id_info>
  <brief_title>To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension</brief_title>
  <official_title>A Two Part Study Including a Randomized, Double Blind, Placebo Controlled, Multiple Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LFF269 After b.i.d Dosing in Healthy Volunteers and an Open Label, Multiple Dose Pharmacokinetics Study in Hypertension Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to enable optimal dose selection of LFF269 for potential future
      studies by providing additional information about the compounds safety, tolerability,
      pharmacokinetic and pharmacodynamic profiles.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of healthy volunteers reported with adverse events as an assessment of safety and tolerability (Part 1)</measure>
    <time_frame>10 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval Tau (AUCtau)[Part 1- Healthy volunteers]</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed maximum plasma concentration following drug administration (Cmax) at day 1 [Part 1- Healthy volunteers]</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval Tau (AUCtau) [Part 2- Patients with hypertension]</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed maximum plasma concentration following drug administration (Cmax) at day 1 [Part 2 - Patients with hypertension]</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to the end of the dosing interval tau at steady state (AUCtau,ss) [Part 1- Healthy volunteers]</measure>
    <time_frame>Day 10</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma  concentration-time curve from time zero to the end of the dosing interval tau at steady state (AUCtau,ss) [Part 2 - Patients with hypertension]</measure>
    <time_frame>Day 5</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed maximum plasma concentration following drug administration at steady state (Cmax,ss) [Part 2 - Patients with hypertension]</measure>
    <time_frame>Up to Day 5</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed maximum plasma concentration following drug administration at steady state (Cmax,ss) [Part 1- Healthy volunteers]</measure>
    <time_frame>Up to Day 10</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients reported with adverse events as an assessment of safety and tolerability (Part - 2, Patient with Hypertension)</measure>
    <time_frame>5 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Part 1 - Healthy Volunteers</condition>
  <condition>Part 2 - Patients With Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo to LFF269 (Part 1)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to LFF269 twice daily (b.i.d) for 10 days in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LFF269 (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LFF269  twice daily (b.i.d) for 10 days in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LFF269 (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LFF269  twice daily (b.i.d) for 5 days in patients with hypertension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LFF269</intervention_name>
    <description>LFF269 capsules twice daily (b.i.d)</description>
    <arm_group_label>LFF269 (Part 1)</arm_group_label>
    <arm_group_label>LFF269 (Part 2)</arm_group_label>
    <other_name>LFF269 active</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to LFF269</intervention_name>
    <description>Placebo LFF269 b.i.d for 10 days in healthy volunteers</description>
    <arm_group_label>Placebo to LFF269 (Part 1)</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Part 1

        - Healthy men and women of non-childbearing potential, 18 to 80 years of age inclusive,
        and in good health as determined by past medical history, physical examination, vital
        signs, electrocardiogram, and laboratory tests at screening.

        Part 2

          -  Hypertensive men and women of non-childbearing potential, 18 to 80 years of age
             inclusive.

          -  Patients with mild-to-moderate uncomplicated essential hypertension

        Exclusion Criteria:

        Part 1

          -  History of hypersensitivity or allergy to any of the study drugs or to drugs of
             similar chemical classes.

          -  A history of clinically significant ECG abnormalities.

          -  Known history or current clinically significant arrhythmias.

          -  History of hypertension, adrenal or endocrine disease.

          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive hCG laboratory test.

          -  Women of child-bearing potential, defined as all women physiologically capable of
             becoming pregnant.

          -  Smokers (use of tobacco products in the previous 3 months).

          -  History of immunodeficiency diseases, including a positive HIV (ELISA and Western
             blot) test result.

          -  A positive Hepatitis B surface antigen or Hepatitis C test result.

        Part 2

          -  Pregnant or nursing (lactating) women.

          -  Women of child-bearing potential.

          -  Known history or evidence of a secondary form of hypertension

          -  Type 1 or type 2 diabetes mellitus.

          -  History of heart diseases

          -  A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.

          -  History of immunodeficiency diseases, including a positive HIV (ELISA and Western
             blot) test result.

        Other protocol defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>January 26, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteers, hypertension</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
